---
title: "Procyrion appoints Andrew Davis to lead therapy development"
date: "2025-12-03T09:56:23.000Z"
publishedDate: "3 décembre 2025"
summary: "Procyrion has appointed of Andrew Davis as chief commercial officer, effective immediately. Davis will lead Procyrion’s therapy development with a focus on trial enrolment, key opinion leader (KOL) engagement, podium strategy and advancing all early market development activities essential for future commercialisation of the Aortix percutaneous mechanical circulatory support (pMCS) technology."
importance: ""
sourceUrl: "https://cardiovascularnews.com/procyrion-appoints-andrew-davis-to-lead-therapy-development/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2025-12-03-procyrion-appoints-andrew-davis-to-lead-therapy-development"
imageUrl: "http://cardiovascularnews.com/wp-content/uploads/sites/14/2025/12/ADavis-2-Headshot-2.28_edited.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/procyrion-appoints-andrew-davis-to-lead-therapy-development/"
---

![Procyrion appoints Andrew Davis to lead therapy development](http://cardiovascularnews.com/wp-content/uploads/sites/14/2025/12/ADavis-2-Headshot-2.28_edited.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/procyrion-appoints-andrew-davis-to-lead-therapy-development/*

## L’essentiel

Procyrion has appointed of Andrew Davis as chief commercial officer, effective immediately. Davis will lead Procyrion’s therapy development with a focus on trial enrolment, key opinion leader (KOL) engagement, podium strategy and advancing all early market development activities essential for future commercialisation of the Aortix percutaneous mechanical circulatory support (pMCS) technology.

## Lien source

https://cardiovascularnews.com/procyrion-appoints-andrew-davis-to-lead-therapy-development/
